ALP Bio

Stub active Updated Apr 30, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Schlieren, Switzerland
Founded 2025
Latest Stage Pre-Seed
Total Raised $2.2M
Website https://alp.bio
Sector
biotech ai drug-discovery healthcare life-sciences

Founders

Anatol Ehrlich Co-Founder
Punit Mehra Co-Founder & Chief Business Officer
Lucas Schaus Co-Founder
Christian Vahlensieck Co-Founder

About

ALP Bio is a Schlieren, Switzerland–based biotech building a hybrid platform that combines human immune organoid biology with generative AI to predict and reduce immunogenicity risk in antibody drug development 12. The company was founded in 2025 and operates across Switzerland and the United States 12.

Funding History

Date Round Amount Lead Co-investors
2026-04-30 Pre-Seed $2.2M 42CAP Venture Kick, strategic angel investors 12

What Investors Say

No independently sourced investor quotes found.

What Founders Say

Punit Mehra, Chief Business Officer: “Venture Kick’s early backing… gave us the runway to validate the concept of our platform in front of real partners” 1.

Sources

  1. Venture Kick, “ALP Bio raises USD 2.2M pre-seed to address immunogenicity risk in antibody development,” April 30, 2026. https://www.venturekick.ch/ALP-Bio-raises-USD-22M-preseed-to-address-immunogenicity-risk-in-antibody-development↩↩↩↩

  2. EU-Startups, “Swiss BioTech startup ALP Bio raises €1.9 million to advance immune organoid and AI platform,” April 30, 2026. https://www.eu-startups.com/2026/04/swiss-biotech-startup-alp-bio-raises-e1-9-million-to-advance-immune-organoid-and-ai-platform/↩↩↩